Oxidation pathway and exacerbations in COPD: the role of NAC

Prevention of Acute Exacerbations of COPD

(2015) Gerard J. Criner et al.   CHEST

Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives

(2015) Mario Cazzola et al.   DRUGS

Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy

(2015) Luigino Calzetta et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

COPD: balancing oxidants and antioxidants

(2015) Bernard Fischer et al.   International Journal of Chronic Obstructive Pulmonary Disease

Effect of N-acetylcysteine in COPD patients with different microsomal epoxide hydrolase genotypes

(2015) Jianqing Zhang et al.   International Journal of Chronic Obstructive Pulmonary Disease

Benefits of High-Dose N-Acetylcysteine to Exacerbation-Prone Patients With COPD

(2014) Hoi Nam Tse et al.   CHEST

Oxidative Stress and Respiratory System: Pharmacological and Clinical Reappraisal of N-Acetylcysteine

(2014) Pierachille Santus et al.   COPD-Journal of Chronic Obstructive Pulmonary Disease

Defining Phenotypes in COPD: An Aid to Personalized Healthcare

(2014) Andrea Segreti et al.   Molecular Diagnosis & Therapy

Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease

(2014) Hoi Nam Tse et al.   International Journal of Chronic Obstructive Pulmonary Disease

Oxidative stress and free radicals in COPD – implications and relevance for treatment

(2014) Wolfgang Domej et al.   International Journal of Chronic Obstructive Pulmonary Disease

Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial

(2014) Jin-Ping Zheng et al.   Lancet Respiratory Medicine

N-acetylcysteine in COPD may be beneficial, but for whom?

(2014) Mario Cazzola et al.   Lancet Respiratory Medicine

High-Dose N-Acetylcysteine in Stable COPD

(2013) Hoi Nam Tse et al.   CHEST

Oxidative Stress in COPD

(2013) Paul A. Kirkham et al.   CHEST

Existing and potential therapeutic uses for N-acetylcysteine: The need for conversion to intracellular glutathione for antioxidant benefits

(2013) Gordon F. Rushworth et al.   PHARMACOLOGY & THERAPEUTICS

Priming of beta-2 agonist and antimuscarinic induced physiological responses induced by 1200mg/day NAC in moderate to severe COPD patients: A pilot study

(2013) Ravikumar Sinojia et al.   RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY

Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients

(2013) Jan De Backer et al.   International Journal of Chronic Obstructive Pulmonary Disease

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

(2013) Jadwiga A Wedzicha et al.   Lancet Respiratory Medicine

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

(2012) Jørgen Vestbo et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling

(2012) Paul D. Ray et al.   CELLULAR SIGNALLING

Antioxidant pharmacological therapies for COPD

(2012) Irfan Rahman et al.   CURRENT OPINION IN PHARMACOLOGY

N-acetyl-l-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)

(2011) Manuel Mata et al.   BIOCHEMICAL PHARMACOLOGY

The short, the long and the “ultra-long”: Why duration of bronchodilator action matters in chronic obstructive pulmonary disease

(2010) Kai M. Beeh et al.   ADVANCES IN THERAPY

N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus

(2009) Janina Geiler et al.   BIOCHEMICAL PHARMACOLOGY

Effect of N-Acetylcysteine on Air Trapping in COPD

(2009) David Stav et al.   CHEST

Inhaled muscarinic antagonists for COPD—does an anti-inflammatory mechanism really play a role?

(2009) Michael Trevethick et al.   CURRENT OPINION IN PHARMACOLOGY

Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype

(2009) Ji-Hyun Lee et al.   RESPIRATORY MEDICINE

Outcomes for COPD pharmacological trials: from lung function to biomarkers

(2008) M. Cazzola et al.   EUROPEAN RESPIRATORY JOURNAL